Is AstraZeneca a Buy as It Eyes the Weight Loss Market?
Express News | Bernstein: The target price for astrazeneca has been lowered from 20,000 pence to 18,000 pence.
AstraZeneca: Overcoming Short-term Challenges With Robust Long-term Potential
AstraZeneca Director Bolsters Stake With Share Purchase
Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)
The ADC therapy jointly developed by astrazeneca and Daiichi Sankyo has submitted a marketing application to the FDA.
On November 13, Gelonghui announced that astrazeneca and Daiichi Sankyo have submitted a Biologics License Application (BLA) for their jointly developed Trop2 targeted antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) based on feedback from the usa FDA, seeking accelerated approval for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, who have previously received systemic treatment (including EGFR targeted therapy).